Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forimtamig in Relapsed or Refractory Multiple Myeloma
NCT04557150Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2020
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of forimtamig in multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events at 104 weeks and Percentage of Participants with Dose Limiting Toxicities at 35 days. Started Nov 2020; status: completed.
02
Drugs
forimtamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04557150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557150.